Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection
Hepatitis B, Chronic
About this trial
This is an interventional treatment trial for Hepatitis B, Chronic focused on measuring HBeAg negative, HLA-A*02;01 Positive, T Cell Receptor (TCR)
Eligibility Criteria
Inclusion Criteria: ≥ 18 years old at time of informed consent HLA-A*02:01 positive Documented evidence of CHB based on one of the following: a. Positive HBsAg and HBV DNA at least 6 months prior to the Screening visit; OR b. Historical liver biopsy consistent with CHB infection. Have been receiving entecavir and/or tenofovir (including tenofovir alafenamide) for ≥12months prior to screening and are willing to continue. HBV DNA negative at screening No history of liver cirrhosis AND prior assessment of fibrosis demonstrating non-cirrhotic status at screening Participants of childbearing potential who are sexually active with a non-sterilized partner must agree to use highly effective methods of birth control from the trial screening date until 3 months after the final dose of the study intervention or longer if required by local regulations Exclusion Criteria: Pregnant or lactating persons Known co-infection with any of the following: HIV, Hepatitis C virus, OR Hepatitis D virus Changes in HBeAg status within 3 months prior to the screening visit Known HBV genotype A Gilbert's syndrome Any known pre-existing medical or psychiatric condition that could interfere with the participant's ability to provide informed consent or participate in study conduct, or that may confound study findings including, but not limited to: Immunologically-mediated disease, e.g. inflammatory bowel disease (Crohn's disease, ulcerative colitis), rheumatoid arthritis, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, scleroderma, or sarcoidosis within 5 years of the screening visit. Current or history of any clinically significant cardiac abnormalities/dysfunction, e.g. congestive heart failure, myocardial infarction ≤6 months prior to the screening visit, pulmonary hypertension, complex congenital heart disease, significant arrhythmia, or active cardiac ischemia. Evidence of decompensated liver disease including, but not limited to, a history or presence of clinical ascites, bleeding esophageal varices, hepatorenal syndrome, or hepatic encephalopathy. Significant immunosuppression from, but not limited to immunodeficiency conditions such as common variable hypogammaglobulinemia Evidence of active or suspected malignancy, or a history of malignancy ≤3 years prior to the screening visit (except adequately treated carcinoma in situ, basal cell carcinoma of the skin, or stage 0 HCC that has been treated). NOTE: Participants under evaluation for malignancy are not eligible Receiving or planning to receive systemic immunosuppressive medications during the study or ≤ 2 months prior to Day1, including but not limited to prednisone >10 mg/day (or equivalent), methotrexate, cyclosporine, or interferon. NOTE: Local steroid therapy is allowed (eg, inhaled, otic, ophthalmic, or intra-articular medications) Use of any live vaccines against infectious diseases within 4 weeks of the first planned administration of study intervention or use of any non-live vaccines against infectious diseases within 2 weeks of the first planned administration of study intervention. Treatment with any investigational drug or enrollment in any other clinical study ≤ 3 months prior to Day1, or at any time during participation in the study. Clinical diagnosis of substance abuse with alcohol, narcotics, or cocaine ≤12 months prior to the screening visit, except for those participants monitored in an opioid substitution maintenance program.
Sites / Locations
- University of Southern California Keck School of Medicine
- University Hospitals Cleveland Medical Center Case Western Reserve
- Linear Clinical Research
- St. Vincent's HospitalRecruiting
- Scienta Clinical Research
- Universitair Ziekenhuis Antwerp
- Aarhus University
- Queen Mary HospitalRecruiting
- Pusan National University HospitalRecruiting
- Asan Medical Center
- Gangnam Severance Hospital-Yonsei University Health SystemRecruiting
- SMG-SNU Boramae Medical CenterRecruiting
- Auckland Clinical Studies
- ID Clinic Myslowice
- ARENSIA Exploratory Medicine Research ClinicRecruiting
- Hospital Universitari Vall d'Hebron de BarcelonaRecruiting
- Hospital Ramón and CajalRecruiting
- Hospital Universitario Puerta de Hierro Majadahonda
- Hospital Universitario Virgen de la Victoria
- Kaohsiung Medical University Chung-Ho
- Taipei Veterans General Hospital
- Guy's Hospital, Dept. of Infectious Disease
- Chelsea and Westminster Hospital, Research and Development, Clinical Trials Facility
- Nottingham University Hospitals NHS Trust Biomedical Research CentreRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Part 1: Single Ascending Dose (SAD)
Part 2: Multiple Ascending Doses (MAD)
SAD will be approximately 10 weeks for each participant, comprising a maximum 42-day screening period, a 1-day treatment period involving a single administration of IMC-I109V and a 28-day follow-up period, for a total of 8 visits. Visits will take place on Day -1 and Days 1, 2, 3, 8, 15, 22, and 29. Follow-up may be extended in participants who achieve a decrease in HBsAg of > 0.5 log10 IU/mL at Day 29.
MAD will be approximately 54 weeks for each participant, comprising a maximum 42-day screening period, a 24-week treatment period involving weekly administration of IMC-I109V, and a 24-week follow-up period, with a total of 29 visits. Visits will take place on Day -1 and Days 1, 3 and 8, Weeks 3 (Day 15) through 24, Weeks 28, 36, 48 and 49. Participants who have achieved HBsAg <100 IU/mL at end of Week 24 may be considered for further study treatments of up to Week 48 and follow-up visits every 12 weeks to Week 72. Treatment will be discontinued at Week 16 in participants who have not shown evidence of a response to IMC-I109V, in order to minimize unnecessary drug exposure in participants who are unlikely to achieve reductions in viral biomarkers with further doses.